Industry Insights
-
How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis
3/1/2021
Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. This calculation will determine either how much internal manufacturing capacity is needed or how much it may cost to manufacture at an external contract development and manufacturing company (CDMO).
-
The Potential of In Vivo Gene Therapy in Rare Pediatric Diseases Like Mucopolysaccharidosis Type II
2/26/2021
Data collected from trials as well as REGENEX's gene therapy programs for the treatment of other rare lysosomal storage diseases have the potential to broaden our understanding of AAV gene therapy in the CNS.
-
Cell and Gene Therapies Are Driving Investment Opportunities
2/23/2021
As technology advances in cell and gene therapy and investment continues in these technologies, life-changing and life-saving neurological therapies are an option available to anyone who needs it.
-
Philadelphia’s Talent Pipeline Collaborative Readies Region For Cell And Gene Therapy Job Growth
2/18/2021
On the heels of a 2020 study predicting substantial job growth in the cell and gene therapy sector in Greater Philadelphia, industry leaders in our region have created the Life Science Talent Pipeline Collaborative to ensure a strong talent pool for the future.
-
Developing Future Delivery Models For ATMPs: Practical Considerations
2/17/2021
With a small number of approved cell therapies/ex-vivo gene therapies, and with those approved therapies reaching small patient populations, there is not a proven strategy to answer the questions about large-scale commercial manufacturing. The developers of these processes are taking different strategies for commercial manufacturing as they weigh several factors.
-
Optimizing Site Readiness in Cell Therapy Clinical Trials Through Comprehensive Support
2/16/2021
Providing comprehensive support to sites is a critical factor for cell therapy clinical trial success.
-
Breaking The Bottleneck For Cell And Gene Therapy Studies: Strategies For Creating Clinical Enthusiasm And Selecting Sites
1/19/2021
With several gene and cell therapies currently in development and even more rapidly moving toward the development stage, a big bottleneck in this evolving field is identifying sites with the capability and capacity to conduct these resource-intensive studies.
-
2020 Gene Therapy Progress Wrap-Up
12/22/2020
Over the past 12 months the news has been dominated by the worldwide COVID-19 pandemic, but the work to bring gene and cell therapies to patients has not stopped. Here is a rundown of some of the most interesting developments in gene and cell therapy for the year.
-
Developing A Therapeutic Platform To Enable Immunotherapy For Liver Tumors
12/22/2020
The deep and durable responses achieved in certain indications with immunotherapies have largely eluded those patients suffering with liver tumors.
-
Reflecting On The Meaning Of Our Work In Gene Therapy
12/7/2020
For so many of us in the cell and gene therapy industry, we entered this field because we were deeply motivated by the life-changing potential such therapies, if approved, could have for patients, and by extension, their families, and communities.